II. Indications
- Non-Q-Wave Myocardial Infarction
- High risk Unstable Angina
- Percutaneous Coronary Intervention (PCI)
III. Contraindications
- Recent major bleeding (last 30 days)
- Hemodialysis
- Bleeding Diathesis
- Severe Hypertension (systolic Blood Pressure >200/110 mmHg)
- Prior Hemorrhagic Stroke
IV. Mechanism
- Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
- Inhibits Fibrinogen binding to Platelets
V. Dosing
- General
-
Acute Coronary Syndrome
- Load: 180 mcg/kg IV bolus
- Infuse: 2 mcg/kg/min IV for up to 72 hours
-
Percutaneous Coronary Intervention (PCI)
- Bolus 180 mcg/kg IV immediately before procedure and again 10 minutes after the first dose
- Infuse: 2 mcg/kg/min IV for 18 to 24 hours after procedure (at least 12 hours)
- Renal Impairment (GFR<50 ml/min)
- Decrease infusion rate to 1 mcg/kg/min
-
Obesity (weight >121 kg)
- Maximum bolus dose: 22.6 mg
- Maximum infusion rate 15 mg/hour (7.5 mg/hour if GFR<50 ml/min)
VI. Adverse Effects
- Major Bleeding
-
Thrombocytopenia
- Discontinue if Platelet Count drops to <100,000 Platelets/mm3
VII. Safety
- Pregnancy Category B
- Unknown safety in Lactation
VIII. Resources
IX. References
- Bansal (2023) Eptifibatide, Treasure Island, StatPearls
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI) | A cyclical heptapeptide with anticoagulant activity. Eptifibatide selectively and reversibly binds to and blocks the platelet glycoprotein IIb/IIIa receptor. This prevents the binding of fibrinogen, von Willebrand factor, and other adhesive ligands and leads to an inhibition of platelet aggregation and prevents thrombus development. |
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
MSH | C086648 |
SnomedCT | 116065005, 386998009 |
LNC | LP171395-9 |
English | L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic(1-6)-disulfide, eptifibatide, eptifibatide (medication), eptifibatide [Chemical/Ingredient], Eptifibatide (product), Eptifibatide (substance), Eptifibatide, epifibatide, epifibratide, EPTIFIBATIDE |
Japanese | エプチフィバチド |
Spanish | eptifibatida (producto), eptifibatida (sustancia), eptifibatida |
Ontology: Integrilin (C0950902)
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
MSH | C086648 |
English | Integrilin, eptifibatide (Integrilin), Integrelin, Pfizer brand of eptifibatide, GlaxoSmithKline UK brand of eptifibatide, integrelin, integrilin, Cor brand of eptifibatide, Essex brand of eptifibatide, Key brand of eptifibatide |